Ki67 and Bcl-2 immunoexpression in primitive urothelial bladder carcinoma

Romanian Journal of Morphology and Embryology

Volumn 53, Issue 3, 2012, Pages 521-525

  Enache, M ^a   Simionescu, Cristiana ^a   Lascu, Luana Corina ^b  

^a UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^b EMERGENCY COUNTY HOSPITAL   (Romania)

Author keywords

Bcl 2; Immunohistochemistry; Ki67; Urothelial carcinoma

Indexed keywords

EID: 84867029902     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010, CA Cancer J Clin, 2010, 60(5):277-300.
2. Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis, 2006, 27(3):361-373.
3. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management, Cancer Pract, 2002, 10(6):311-322.
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int J Cancer, 2010, 127(12):2893-2917.
5. Cookson MS. The surgical management of muscle invasive bladder cancer: a contemporary review, Semin Radiat Oncol, 2005, 15(1):10-18.
6. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients, J Clin Oncol, 2001, 19(3):666-675.
7. Lopez-Beltran A, Cheng L. Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance, Pathology, 2003, 35(6):484-491.
8. Lopez-Beltran A, Sauter G, Gasser T, Tumours of the urinary system. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds). Pathology and genetics of tumours of the urinary system and male genital organs, World Health Organization Classification of Tumours, IARC Press, Lyon, 2004, 89-154.
9. Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors, Cancer Res, 1993, 53(14):3241-3245.
10. Desai S, Lim SD, Jimenez RE, Chun T, Keane TE, McKenney JK, Zavala-Pompa A, Cohen C, Young RH, Amin MB. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia, Mod Pathol, 2000, 13(12):1315-1323.
11. Compérat E, Camparo P, Haus R, Chartier-Kastler E, Bart S, Delcourt A, Houlgatte A, François R, Capron F, Vieillefond A. Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases, Virchows Arch, 2006, 448(3):319-324.
12. Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Gakiopoulou H, Dimopoulos MA. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates, Hum Pathol, 1998, 29(2):146-154.
13. van Diest PJ, Brugal G, Baak JPA. Proliferation markers in tumours: interpretation and clinical value, J Clin Pathol, 1998, 51(10):716-724.
14. Cattoretti G, Becker MH, Key G, Duchrow M, Schlüter C, Galle J, Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalinfixed paraffin sections, J Pathol, 1992, 168(4):357-363.
15. rd, Wolkov HB, Sandler HM, Shipley WU, Pollack A. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10, Clin Cancer Res, 2004, 10(12 Pt 1):4118-4124.
16. Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, Hotz S, Raines S, Ming ME, Wahl P, Guerry D. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma, J Clin Oncol, 2005, 23(31):8048-8056.
17. Limas C, Bigler A, Bair R, Bernhart P, Reddy P. Proliferative activity of urothelial neoplasms: comparison of BrdU incorporation, Ki67 expression, and nucleolar organiser regions, J Clin Pathol, 1993, 46(2):159-165.
18. Stepan A, Simionescu C, Mǎrgǎritescu C, Ciurea R. P16, c-erbB2 and Ki67 immunoexpression in urothelial carcinomas of the bladder, Rom J Morphol Embryol, 2011, 52(2):653-658.
19. Helpap B, Köllermann J. Assessment of basal cell status and proliferative patterns in flat and papillary urothelial lesions: a contribution to the new WHO classification of urothelial tumors of the urinary bladder, Hum Pathol, 2000, 31(6):745-750.
20. Quintero A, Alvarez-Kindelan J, Luque RJ, Gonzalez-Campora R, Requena MJ, Montironi R, Lopez-Beltran A. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder, J Clin Pathol, 2006, 59(1):83-88.
21. Su JS, Arima K, Hasegawa M, Franco OE, Yanagawa M, Sugimura Y, Kawamura J. Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma, Hinyokika Kiyo, 2003, 49(11): 649-658.
22. Pich A, Chiusa L, Formiconi A, Galliano D, Bortolin P, Comino A, Navone R. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder, Cancer, 2002, 95(4): 784-790.
23. Popov Z, Hoznek A, Colombel M, Bastuji-Garin S, Lefrere-Belda MA, Bellot J, Abboh CC, Mazerolles C, Chopin DK. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder, Cancer, 1997, 80(8):1472-1481.
24. Suwa Y, Takano Y, Iki M, Asakura T, Noguchi S, Masuda M. Prognostic significance of Ki-67 expression in transitional cell bladder carcinoma after radical cystectomy, Pathol Res Pract, 1997, 193(8):551-556.
25. Korkolopoulou P, Christodoulou P, Kapralos P, Exarchakos M, Bisbiroula A, Hadjiyannakis M, Georgountzos C, Thomas-Tsagli E. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer, Pathol Res Pract, 1997, 193(11-12):767-775.
26. Krause FS, Feil G, Bichler KH. Immunohistochemical examinations (Ki67, p53, nm23) and DNA cytophotometry in bladder cancer, Anticancer Res, 2000, 20(6D):5023-5028.
27. Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, Nielsen ME, Müller SC, Rigaud J, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, Shariat SF. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer, J Natl Cancer Inst, 2009, 101(2):114-119.
28. McKnight JJ, Gray SB, O'Kane HF, Johnston SR, Williamson KE. Apoptosis and chemotherapy for bladder cancer, J Urol, 2005, 173(3):683-690.
29. Leonardo C, Mattace Raso D, Albino G, Pozza M, Gallucci M. The role of Bcl-2 and Bax genes for urinary bladder cancer relapse, Eur Urol, 2003, 2(1 Suppl 2):45.
30. Shiina H, Igawa M, Urakami S, Honda S, Shirakawa H, Ishibe T. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder, J Clin Pathol, 1996, 49(5):395-399.
31. Ong F, Moonen LM, Gallee MP, ten Bosch C, Zerp SF, Hart AA, Bartelink H, Verheij M. Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53, Radiother Oncol, 2001, 61(2):169-175.
32. Şen Türk N, Aybek Z, Düzcan E. Ki-67, p53, Bcl-2 and Bax expression in urothelial carcinomas of urinary bladder, Türk Patoloji Dergisi, 2010, 26(1):25-30.
33. Gonzalez-Campora R, Davalos-Casanova G, Beato-Moreno A, Garcia-Escudero A, Pareja Megia MJ, Montironi R, Lopez-Beltran A. BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma, Cancer Lett, 2007, 250(2):292-299.